AIP and heart failure: CaMKII inhibitors, such as autocamtide inhibitory peptide (AIP), CaMKIIN, AS105, and hesperidin, could provide a dual benefit for heart failure by enhancing contractility through the stabilization of Ca2+ cycling and by reducing arrhythmic risk.This would be particularly advantageous for HFpEF patients, who currently lack effective treatment options, through the direct targeting of Ca2+ dysregulation driven by inflammation and CaMKII activation—mechanisms not effectively addressed by conventional heart failure therapies or non-specific anti-inflammatory agents [29,30].